Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Automated cell therapy manufacturing could help Cellares and Papillon Therapeutics advance PPL-001 toward clinical development for Friedreich’s ataxia. Representative image.
Pharma & Biotech

Can Cellares automation move Papillon’s PPL-001 closer to a Friedreich’s ataxia trial?

Cellares will automate PPL-001 manufacturing for Friedreich’s ataxia, but IND-enabling work and human evidence remain ahead.

Read More
eXmoor Pharma and Evox Therapeutics complete an exosome gene-editing technology transfer supporting future manufacturing of the MSH3-targeted Huntington’s disease programme. Representative image.
Pharma & Biotech

Evox Therapeutics advances MSH3 Huntington’s disease programme through eXmoor Pharma transfer

eXmoor Pharma and Evox complete an exosome gene-editing transfer, advancing the CMC path for Evox’s Huntington’s disease programme.

Read More
Evonik and evitria’s eviCHO Expression Kit targets faster, more consistent CHO-K1 protein production for early biologics research. Representative image.
Pharma & Biotech

Evonik and evitria say this CHO kit can cut biologics troubleshooting. Will laboratories make the switch?

Evonik and evitria launch the eviCHO Expression Kit to simplify CHO-K1 protein production, but adoption will depend on reproducible lab performance.

Read More
Gilead Sciences and Merck’s investigational once-weekly HIV pill maintained virological suppression in the Phase 3 ISLEND-1 and ISLEND-2 trials. Representative image.
Pharma & Biotech

Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes

Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.

Read More
Beam Healthcare and Simvuly are expanding same-day virtual access to board-certified specialists for clinicians across the United States. Representative image.
Pharma & Biotech

Can Beam Healthcare and Simvuly turn same-day specialist advice into a practical national care model?

Beam Healthcare and Simvuly take specialist consults nationwide, but workflow, reimbursement and measurable outcomes will decide adoption.

Read More
Pheast Therapeutics’ PHST001 anti-CD24 research highlights a macrophage-directed approach to targeting solid tumors as Phase 1 combination testing advances. Representative image.
Pharma & Biotech

Pheast Therapeutics strengthens PHST001 case with peer-reviewed anti-CD24 cancer research

Pheast Therapeutics’ PHST001 gains peer-reviewed CD24 data as Phase 1 combination cohorts advance. See what the evidence means.

Read More
Helus Pharma’s HLP003 moves closer to a pivotal Phase 3 depression data readout after the APPROACH study completed enrolment ahead of schedule. Representative image.
Pharma & Biotech

Helus Pharma finished Phase 3 enrolment early, but HLP003’s decisive test is still ahead

Helus Pharma completes APPROACH enrolment as HLP003 heads toward a pivotal Phase 3 depression data readout in the fourth quarter of 2026.

Read More
JCR Pharmaceuticals’ IZCARGO UAE marketing authorization expands access to a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome. Representative image.
Pharma & Biotech

IZCARGO has moved beyond Japan, but JCR Pharmaceuticals’ real test begins after the UAE authorization

JCR Pharmaceuticals’ UAE authorization for IZCARGO opens a new market, but reimbursement, supply and Phase III evidence will shape its impact.

Read More
Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.
Pharma & Biotech

TP101 drove near-complete tumor regression in mice. What must Tract Bio prove next?

Tract Bio's AACR posters link TP101 and stemECHO to drug-resistant cancer stem cells, while IND work and clinical validation remain the key hurdles ahead.

Read More
Automated tissue-slide processing highlights how the Parhelia Biosciences and Sirona Dx partnership aims to improve the scalability and reproducibility of spatial biology research workflows. Representative image.
Pharma & Biotech

Can Parhelia Biosciences and Sirona Dx solve the scale problem holding spatial biology back?

Parhelia and Sirona Dx are tackling spatial biology’s scale problem with automated workflows, but multisite validation remains the decisive test ahead.

Read More